Skip to main content


TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Patient Support Program

Receive updates and information from the TYVASO Support Program

Are you considering or already taking TYVASO? Please complete the form below to connect with us for helpful updates, information, and support.


By clicking the SUBMIT button, I understand that I am giving United Therapeutics Corporation and its affiliates and business partners permission to use my personal information to provide me with information related to the TYVASO Support Program, as well as treatment options and services provided by United Therapeutics. I understand that United Therapeutics and its contractors will not sell or rent my personal information. I understand I may revoke my permission at any time by clicking the unsubscribe link at the bottom of the page. For more information, please read the Privacy Policy.

If you have been prescribed TYVASO DPI or TYVASO for PH-ILD, you can get support from a United Therapeutics Virtual Patient Educator* through the Archways program.

*United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your healthcare provider with any specific questions or concerns about your treatment.

DPI=dry powder inhaler.